Trek Financial LLC Raises Position in Gilead Sciences, Inc. $GILD

Trek Financial LLC lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 510.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,594 shares of the biopharmaceutical company’s stock after purchasing an additional 13,041 shares during the period. Trek Financial LLC’s holdings in Gilead Sciences were worth $1,914,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock worth $14,863,487,000 after purchasing an additional 2,113,692 shares during the last quarter. Invesco Ltd. increased its stake in shares of Gilead Sciences by 12.0% during the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock worth $1,680,505,000 after purchasing an additional 1,618,453 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Gilead Sciences by 4.2% during the 3rd quarter. Legal & General Group Plc now owns 10,210,599 shares of the biopharmaceutical company’s stock worth $1,133,376,000 after purchasing an additional 414,454 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Gilead Sciences by 5.9% during the 3rd quarter. Ameriprise Financial Inc. now owns 7,148,405 shares of the biopharmaceutical company’s stock worth $793,506,000 after purchasing an additional 400,002 shares during the last quarter. Finally, Nordea Investment Management AB grew its stake in Gilead Sciences by 16.5% in the 4th quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock valued at $630,056,000 after buying an additional 726,101 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the transaction, the chief executive officer directly owned 632,567 shares of the company’s stock, valued at $81,702,353.72. This trade represents a 1.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total transaction of $463,290.00. Following the completion of the transaction, the chief financial officer directly owned 167,779 shares of the company’s stock, valued at approximately $25,910,110.97. The trade was a 1.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 63,000 shares of company stock valued at $9,238,250 in the last three months. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Up 1.1%

Shares of NASDAQ:GILD opened at $134.94 on Wednesday. The firm has a fifty day moving average price of $138.79 and a two-hundred day moving average price of $133.08. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. Gilead Sciences, Inc. has a one year low of $97.86 and a one year high of $157.29. The company has a market cap of $167.54 billion, a price-to-earnings ratio of 18.38 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period last year, the firm earned $1.81 EPS. The business’s quarterly revenue was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Analysts anticipate that Gilead Sciences, Inc. will post -0.86 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be issued a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on GILD shares. Argus lifted their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Bank of America set a $162.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, February 11th. Jefferies Financial Group started coverage on shares of Gilead Sciences in a research note on Tuesday, March 10th. They issued a “buy” rating and a $180.00 price objective for the company. UBS Group lifted their price objective on shares of Gilead Sciences from $145.00 to $155.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, Mizuho lifted their price objective on shares of Gilead Sciences from $140.00 to $170.00 and gave the company an “outperform” rating in a research note on Wednesday, February 18th. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $157.04.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.